Price Alert

Alnylam Pharmaceuticals I... (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

456.35

-4.64 (-1.01%)

At close: Oct 03, 2025, 3:59 PM

455.47

-0.19%

After-hours: Oct 03, 2025, 07:00 PM EDT

Alnylam Pharmaceuticals Statistics

Share Statistics

Alnylam Pharmaceuticals has 131.08M shares outstanding. The number of shares has increased by 1.63% in one year.

Shares Outstanding	131.08M
Shares Change (YoY)	1.63%
Shares Change (QoQ)	0.53%
Owned by Institutions (%)	99.99%
Shares Floating	126.15M
Failed to Deliver (FTD) Shares	183
FTD / Avg. Volume	0.02%

Short Selling Information

The latest short interest is 3.72M, so 2.87% of the outstanding shares have been sold short.

Short Interest	3.72M
Short % of Shares Out	2.87%
Short % of Float	3.8%
Short Ratio (days to cover)	3.05

Valuation Ratios

The PE ratio is -107.99 and the forward PE ratio is 75.45. Alnylam Pharmaceuticals's PEG ratio is 2.79.

PE Ratio	-107.99
Forward PE	75.45
PS Ratio	13.36
Forward PS	12.2
PB Ratio	447.73
P/FCF Ratio	-705.29
PEG Ratio	2.79

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Alnylam Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.78, with a Debt / Equity ratio of 19.32.

Current Ratio	2.78
Quick Ratio	2.71
Debt / Equity	19.32
Debt / EBITDA	-7.25
Debt / FCF	-30.43
Interest Coverage	-1.25

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$1.01M
Profits Per Employee	$-124.73K
Employee Count	2,230
Asset Turnover	0.53
Inventory Turnover	4.12

Taxes

Income Tax	-99.22M
Effective Tax Rate	26.29%

Stock Price Statistics

The stock price has increased by 70.29% in the last 52 weeks. The beta is 0.35, so Alnylam Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.35
52-Week Price Change	70.29%
50-Day Moving Average	439.22
200-Day Moving Average	313.32
Relative Strength Index (RSI)	54.59
Average Volume (20 Days)	1,154,287

Income Statement

In the last 12 months, Alnylam Pharmaceuticals had revenue of 2.25B and earned -278.16M in profits. Earnings per share was -2.16.

Revenue	2.25B
Gross Profit	1.92B
Operating Income	-176.88M
Net Income	-278.16M
EBITDA	-178.85M
EBIT	-235.52M
Earnings Per Share (EPS)	-2.16

Full Income Statement

Balance Sheet

The company has 966.43M in cash and 1.3B in debt, giving a net cash position of -329.62M.

Cash & Cash Equivalents	966.43M
Total Debt	1.3B
Net Cash	-329.62M
Retained Earnings	-7.29B
Total Assets	4.57B
Working Capital	2.34B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -8.31M and capital expenditures -34.28M, giving a free cash flow of -42.59M.

Operating Cash Flow	-8.31M
Capital Expenditures	-34.28M
Free Cash Flow	-42.59M
FCF Per Share	-0.33

Full Cash Flow Statement

Margins

Gross margin is 85.62%, with operating and profit margins of -7.87% and -12.37%.

Gross Margin	85.62%
Operating Margin	-7.87%
Pretax Margin	-16.79%
Profit Margin	-12.37%
EBITDA Margin	-7.95%
EBIT Margin	-7.87%
FCF Margin	-1.89%

Dividends & Yields

ALNY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ALNY is $450, which is -1.4% lower than the current price. The consensus rating is "Buy".

Price Target	$450
Price Target Difference	-1.4%
Analyst Consensus	Buy
Analyst Count	27

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	6.91
Piotroski F-Score	1